10.09.2018 Issue 422

Visit HealthEconomics.Com Subscribe to Newsletters  |  Contact Us  |  Forward to a Friend
Sponsored by:

This Week's HEOR Round-up
The Top Story in HEOR: Latest Headlines in HEOR:

HealthEconomics.Com Survey Seeks Insights on HEOR, RWE Sourcing, Procurement and Contracting

Monday, October 8

Sourcing, procurement, and contracting have made their way into HEOR and RWE, and they come with some significant challenges in matching buyers and suppliers in a way that optimizes the relationship. We are conducting this survey to identify opportunities that will help deliver faster HEOR and RWE science, expedite market access, and improve patient outcomes.

New, Mysterious Advocacy Group Defends High Drug Costs

Rising Insulin Prices, Complex System Ensnare Diabetics

ICER Report: Inotersen, Patisiran Offer Health Benefits

ISPOR Offering Webinar on Survival Analysis Oct. 22

AMCP Conducting Survey on Barriers to Biologics

Republican Lobbying Firm Behind APMI

Prime Therapeutics, Janssen OK Value-Based Deal for Stelara

ICER Report Highlights Antiandrogen Therapies for Early-State Prostate Cancer

TriNetX Announces New Research Tools

ISPOR 2019 Issues Call for Abstracts

Research Associate III- Patient-Centered Research- Hammersmith

Healthcare Software Product Manager

Health Economist

Lead Health Economist

Associate Director Health Economics

Associate Director Real World Evidence (RWE) and Epidemiology

Associate Director/ Director, Medical Affairs- HEOR

Watson Health - Outcomes Research Leader (HEOR)

Industry Spotlight

Conferences Webinars
13th Value-Based Oncology Management
    October 10-11, Scottsdale, Arizona

Colloquium 2018: The Essentials of Value-Based Care
    October 10-12, Washington, D.C.

2nd Annual Specialty Drug Management
    October 11-12, Philadelphia, Pennsylvania

Specialty Drug Management Innovations for Health Plans
    October 11-12, Philadelphia, Pennsylvania

ISMPP West 2018
   October 11-12, San Diego, California

ICER Reports’ Impact on US Drug Coverage Decisions: Passing Fad or Game Changer?
    October 9

Unlocking the Power of Pragmatic Clinical Trials: Learnings from Real-World Examples
    October 11

HIPAA and Business Associates - New Responsibilities and Obligations
   October 11

RWE Driven Drug Development
    October 11

Conference of the Week Webinar of the Week Job of the Week Link of the Week

Syndicated Reports White Papers
Payer Engagement: Benchmarking Team Structure and Activity

Benchmarking Market Access Strategies for High-Cost Drugs, Biologics

Blockchain: Transformational Change for Pharma?

Benchmarking Market Access Strategies for High-Cost Drugs and Biologics

HTA in Europe: Key Success Factors for Positive HTA Recommendations

Paying for Digital Health: Payer Insights

Benchmarking Pharma’s MSL Capabilities

Biosimilars: US Payer Perspectives

Health Care USA: A Cancer on the American Dream

The Utility of ICER Reports for Private Payer Drug Coverage Decision-Making: Cost-Effectiveness Assessments

Advancing Biosimilar Sustainability in Europe

A Holistic Approach to Payment Accuracy Helps Drive Cost Savings

Improving Patient Matching with a Simple Plug-In

Real-World Evidence in the Cloud: How Technology is Revealing the Big Picture in Pharma

How Payers Can Save an Average of $25,579 Per Patient by Eliminating Unwarranted, Non-Evidence-Based Cancer Treatment

Special Thanks to Our Partners:
            Evidera   HealthCore     University of FL  Xcenda
        OM1Parexel   Jefferson   Dymaxium   Precision Xtract
          Pharmerit    eMax Health   SciformixEvidence Partners
          ICON    Truven